Updates in the Risk and Treatment of Hyperkalemia in CKD Patients
By:
Alice M. Sheridan Renal Division, Brigham and Women’s Hospital, Boston, Massachusetts

Search for other papers by Alice M. Sheridan in
Current site
Google Scholar
PubMed Close
Volume/Issue:
Volume 23: Issue 2
Published Online:
Jun 2024
Restricted access
Purchase Print On-Demand ASN Members Sign In Here
  • Collapse
  • Expand
Cover Nephrology Self-Assessment Program
Copyright:
Copyright © 2024 by the American Society of Nephrology 2024
Page Count:
3
Article Category:
Research Article
Print Publication Date:
01 Jun 2024
Published Online:
Jun 2024
  • 1.

    Palmer BF, Clegg DJ: Physiology and pathophysiology of potassium homeostasis: Core curriculum 2019. Am J Kidney Dis 74: 682–695, 2019 PubMed

  • 2.

    Ayach T, Nappo RW, Paugh-Miller JL, Ross EA: Postoperative hyperkalemia. Eur J Intern Med 2: 106–111, 2015 PubMed

  • 3.

    Perazella MA, Biswas P: Acute hyperkalemia associated with intravenous epsilon-aminocaproic acid therapy. Am J Kidney Dis 33: 782–785, 1999 PubMed

  • 4.

    Segawa K, Nishiyama M, Mori I, Kubota T, Takahashi MP: Hyperkalemic periodic paralysis associated with a novel missense variant located in the inner pore of Nav1.4. Brain Dev 45: 205–211, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Wilson FH, Disse-Nicodème S, Choate KA, Ishikawa K, Nelson-Williams C, Desitter I, et al.: Human hypertension caused by mutations in WNK kinases. Science 293: 1107–1112, 2001 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 6.

    Grimm PR, Coleman R, Delpire E, Welling PA: Constitutively active SPAK causes hyperkalemia by activating NCC and remodeling distal tubules. J Am Soc Nephrol 28: 2597–2606, 2017 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    McCormick JA, Ellison DH: Nephron remodeling underlies hyperkalemia in familial hyperkalemic hypertension. J Am Soc Nephrol 28: 2555–2557, 2017 PubMed

  • 8.

    Cornelius RJ, Maeoka Y, McCormick JA: Renal effects of cullin 3 mutations causing familial hyperkalemic hypertension. Curr Opin Nephrol Hypertens 32: 335–343, 2023 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al.: 2022 AHA/ACC/HFSA guideline for the management of heart failure: Executive summary: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 145: e876–e894, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al.; ESC Scientific Document Group: 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42: 3599–3726, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    KDIGO CKD Work Group: KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Int 105[4S]: S117–S314, 2024 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al.: Diabetes management in chronic kidney disease: A consensus report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care 45: 3075–3090, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Rassi AN, Cavender MA, Fonarow GC, Cannon CP, Hernandez AF, Peterson ED, et al.: Temporal trends and predictors in the use of aldosterone antagonists post-acute myocardial infarction. J Am Coll Cardiol 61: 35–40, 2013 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, et al.; Heart Failure Long-Term Registry Investigators Group: Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail 22: 1378–1389, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J: Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 21[Suppl]: S212–S220, 2015 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Leon SJ, Whitlock R, Rigatto C, Komenda P, Bohm C, Sucha E, et al.: Hyperkalemia-related discontinuation of renin-angiotensin-aldosterone system inhibitors and clinical outcomes in CKD: A population-based cohort study. Am J Kidney Dis 80: 164–173.e1, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Palmer BF, Clegg DJ: Managing hyperkalemia to enable guideline-recommended dosing of renin-angiotensin-aldosterone system inhibitors. Am J Kidney Dis 80: 158–160, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Agarwal R, Pitt B, Palmer BF, Kovesdy CP, Burgess E, Filippatos G, et al.: A comparative post hoc analysis of finerenone and spironolactone in resistant hypertension in moderate-to-advanced chronic kidney disease. Clin Kidney J 16: 293–302, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Neuen BL, Oshima M, Agarwal R, Arnott C, Cherney DZ, Edwards R, et al.: Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: A meta-analysis of individual participant data from randomized, controlled trials. Circulation 145: 1460–1470, 2022 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Neuen BL, Oshima M, Perkovic V, Agarwal R, Arnott C, Bakris G, et al. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: The CREDENCE trial. Eur Heart J 42: 4891–4901, 2021 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Agarwal R, Rossignol P, Romero A, Garza D, Mayo MR, Warren S, et al.: Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): A phase 2, randomised, double-blind, placebo-controlled trial. Lancet 394: 1540–1550, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Noel JA, Bota SE, Petrcich W, Garg AX, Carrero JJ, Harel Z, et al.: Risk of hospitalization for serious adverse gastrointestinal events associated with sodium polystyrene sulfonate use in patients of advanced age. JAMA Intern Med 179: 1025–1033, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Palmer BF, Carrero JJ, Clegg DJ, Colbert GB, Emmett M, Fishbane S, et al.: Clinical management of hyperkalemia. Mayo Clin Proc 96: 744–762, 2021 PubMed

  • 24.

    Laureati P, Xu Y, Trevisan M, Schalin L, Mariani I, Bellocco R, et al.: Initiation of sodium polystyrene sulphonate and the risk of gastrointestinal adverse events in advanced chronic kidney disease: a nationwide study. Nephrol Dial Transplant 35: 1518–1526, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 25.

    Bounthavong M, Butler J, Dolan CM, Dunn JD, Fisher KA, Oestreicher N, et al.: Cost-effectiveness analysis of patiromer and spironolactone therapy in heart failure patients with hyperkalemia. PharmacoEconomics 36: 1463–1473, 2018 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Clase CM, Carrero JJ, Ellison DH, Grams ME, Hemmelgarn BR, Jardine MJ, et al.; Conference Participants: Potassium homeostasis and management of dyskalemia in kidney diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies conference. Kidney Int 97: 42–61, 2020 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Galloway CD, Valys AV, Shreibati JB, Treiman DL, Petterson FL, Gundotra VP, et al.; Development and validation of a deep-learning model to screen for hyperkalemia from the electrocardiogram. JAMA Cardiol 4: 428–436, 2019 PubMed

    • PubMed
    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 3274 3274 76
Full Text Views 320 320 20
PDF Downloads 479 479 31